Nottingham-based Albumedix has entered into a definitive agreement to be acquired by life science group Sartorius, a leader in laboratory and bioprocessing technologies for the biopharmaceutical industry.
Through this acquisition, Albumedix and Sartorius expand their solution space with complementary technologies and synergetic competencies, to deliver science-enabled solutions for the entire advanced therapy value chain.
The company will continue to be led by Albumedix’ CEO Jonas S. Møller and its Executive Management team.
Albumedix will become part of the Bioprocess Solutions Division within Sartorius, with the growing Albumedix Campus in Nottingham being established as a centre of excellence in Sartorius dedicated to bio-innovation and GMP-compliant manufacturing of critical raw materials.
Sartorius will look to rapidly invest in the expansion of Albumedix’ innovation capacities.
Jonas S. Møller, CEO of Albumedix, said: “We are delighted to be joining forces with Sartorius and look forward to accelerating our ambitious growth plans in delivering critical solutions to our global customers.
“We have been highly impressed with Sartorius’ knowledge and capabilities in the bioprocessing markets, and we are excited to join this purposeful journey. We believe Sartorius will bring tremendous value by strengthening our market reach and broadening our innovation capacity, as well as significantly scaling up our existing platform. We look forward to continuing our promise of empowering excellence in the life science industry.”
René Fáber, member of the Executive Board for the Bioprocess Solutions Division of Sartorius, said: “Albumedix will be an important addition to Sartorius’ advanced therapy solutions, particularly regarding our cell culture media business, as it will enable us to strengthen our position as a relevant supplier of innovative chemically defined media and critical ancillary materials.
“This market offers high growth potential due to the increasing regulatory requirements as well as rising demand for the use of recombinant human albumin in near-patient applications. Albumedix will also add important formulation excipients to our vaccine production solutions, allowing us to expand our existing customer relationships and forge new ones.”
Under the terms of the agreement, Sartorius, through its French listed subgroup Sartorius Stedim Biotech, will acquire all outstanding shares of Albumedix Ltd. for an agreed purchase price of approximately £415 million. The acquisition is subject to customary closing conditions and is expected to close before the end of the third quarter of 2022.
William Blair acted as financial advisor to Albumedix, and Eversheds Sutherland provided legal counsel. Milbank LLP provided legal counsel to Sartorius.
